INT140411

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2006
Last Reported 2010
Negated 5
Speculated 3
Reported most in Body
Documents 45
Total Number 49
Disease Relevance 62.35
Pain Relevance 8.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Nqo1) oxidoreductase activity (Nqo1) cytoplasm (Nqo1)
Anatomy Link Frequency
spinal cord 4
mere 2
neurons 1
plaques 1
brain 1
Nqo1 (Mus musculus)
Pain Link Frequency Relevance Heat
Spinal cord 600 99.78 Very High Very High Very High
intrathecal 75 99.78 Very High Very High Very High
Multiple sclerosis 465 99.60 Very High Very High Very High
Neuritis 601 99.32 Very High Very High Very High
Glutamate 8 98.68 Very High Very High Very High
agonist 37 98.48 Very High Very High Very High
Central nervous system 1121 97.48 Very High Very High Very High
Inflammation 436 97.32 Very High Very High Very High
alcohol 2 96.92 Very High Very High Very High
addiction 18 90.32 High High
Disease Link Frequency Relevance Heat
Neuromyelitis Optica 4944 100.00 Very High Very High Very High
Disease 1609 100.00 Very High Very High Very High
Autoimmune Disease 404 100.00 Very High Very High Very High
Syndrome 184 100.00 Very High Very High Very High
Transverse Myelitis 385 99.84 Very High Very High Very High
Dengue 34 99.84 Very High Very High Very High
Demyelinating Disease 538 99.80 Very High Very High Very High
Virus Diseases 17 99.80 Very High Very High Very High
Apoptosis 219 99.78 Very High Very High Very High
Multiple Sclerosis 527 99.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Single NADPH-diaphorase positive neurons were occasionally found (Fig. 2B, G).
Gene_expression (neurons) of NADPH-diaphorase in neurons
1) Confidence 0.60 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1373636 Disease Relevance 0.10 Pain Relevance 0
NADPH- Diaphorase histochemistry
Gene_expression (histochemistry) of Diaphorase
2) Confidence 0.52 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1373636 Disease Relevance 0.15 Pain Relevance 0
OA treatment dramatically increased expression of hepatic metallothionein (Mt), and increased the expression of the nuclear factor E2-related factor 2 (Nrf2), NAD(P)H:quinone oxidoreductase 1 (Nqo1), heme oxygenase-1 (Hmox1), and glutamate-cysteine ligases (Gclc and Gclm).
Gene_expression (expression) of Nqo1 associated with glutamate
3) Confidence 0.51 Published 2008 Journal Biochem. Pharmacol. Section Abstract Doc Link 18706400 Disease Relevance 0 Pain Relevance 0.12
NO-generating agents NOR3 (t(1/2)=30min) and SNAP (t(1/2)=5h), but not NOR1 (t(1/2)=1.8min), significantly enhanced NADPH-diaphorase staining in the spinal cord. 8-Br-cGMP also enhanced it similar to that by NOR3, and 8-Br-cAMP and forskolin, an activator of adenylate cyclase, enhanced it moderately.
Gene_expression (staining) of NADPH-diaphorase in spinal cord associated with spinal cord
4) Confidence 0.26 Published 2007 Journal Nitric Oxide Section Abstract Doc Link 17548218 Disease Relevance 0.09 Pain Relevance 0.39
NO-generating agents NOR3 (t(1/2)=30min) and SNAP (t(1/2)=5h), but not NOR1 (t(1/2)=1.8min), significantly enhanced NADPH-diaphorase staining in the spinal cord. 8-Br-cGMP also enhanced it similar to that by NOR3, and 8-Br-cAMP and forskolin, an activator of adenylate cyclase, enhanced it moderately.
Gene_expression (staining) of NADPH-diaphorase in spinal cord associated with spinal cord
5) Confidence 0.26 Published 2007 Journal Nitric Oxide Section Abstract Doc Link 17548218 Disease Relevance 0.09 Pain Relevance 0.39
The target antigen of NMO-IgG was recently identified as aquaporin-4 (AQP4) water channel protein, which is mainly expressed in brain and spinal cord.
Gene_expression (expressed) of NMO in spinal cord associated with neuromyelitis optica and spinal cord
6) Confidence 0.22 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 17146196 Disease Relevance 1.32 Pain Relevance 0.14
Among the patients with NMO, six were NMO-IgG-positive.
Gene_expression (positive) of NMO associated with neuromyelitis optica
7) Confidence 0.19 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 17146196 Disease Relevance 1.50 Pain Relevance 0.11
The principal enzymes with polymorphic variants involved in phase I reactions are the following: CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2, epoxide hydrolase, esterases, NQO1 (NADPH-quinone oxidoreductase), DPD (dihydropyrimidine dehydrogenase), ADH (alcohol dehydrogenase), and ALDH (aldehyde dehydrogenase).
Gene_expression (/) of NQO1 associated with alcohol
8) Confidence 0.19 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654795 Disease Relevance 0 Pain Relevance 0.08
Detection of NMO-IgG or AQP4 autoantibodies is clinically useful for early diagnosis of NMO and its related spectrum disorders (NMOSD), including single attack or recurrent LETM without ON, and recurrent ON without ATM; and especially early distinction between NMOSD and CMS [3].
Gene_expression (Detection) of NMO-IgG associated with neuromyelitis optica, multiple sclerosis, transverse myelitis, demyelinating disease and neuritis
9) Confidence 0.08 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 2.35 Pain Relevance 0.65
Our results are consistent with other reports confirming that both NMO-IgG detected by tissue-based IIFA and AQP4 autoantibodies detected by cell-based IIFA are specific for NMOSD, and that their detection facilitates early distinction of NMOSD from CMS [5,8,10,15].
Gene_expression (detected) of NMO-IgG associated with neuromyelitis optica and multiple sclerosis
10) Confidence 0.08 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 1.48 Pain Relevance 0.26
Our results show that cell-based IIFA detects AQP4 autoantibodies in 78% of NMO patients and 75% of patients having relapsing myelitis with LETM, while tissue-based IIFA detect NMO-IgG in 61% of NMO patients and 50% of patients having relapsing myelitis with LETM.
Gene_expression (detect) of NMO-IgG associated with neuromyelitis optica, transverse myelitis and demyelinating disease
11) Confidence 0.08 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 1.66 Pain Relevance 0.20
The target antigen of NMO-IgG was recently identified as aquaporin-4 (AQP4) water channel protein, which is mainly expressed in brain and spinal cord.
Gene_expression (expressed) of NMO in brain associated with neuromyelitis optica and spinal cord
12) Confidence 0.07 Published 2006 Journal Tohoku J. Exp. Med. Section Abstract Doc Link 17146196 Disease Relevance 1.32 Pain Relevance 0.14
In addition, cell-based IIFA detects AQP4 autoantibodies in 33% of relapsing ON patients while tissue-based IIFA detects NMO-IgG in 22% of this group.
Gene_expression (detects) of NMO-IgG associated with neuromyelitis optica and neuritis
13) Confidence 0.07 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2941752 Disease Relevance 1.66 Pain Relevance 0.23
Weinshenker et al. [9] recently demonstrated that NMO-IgG seropositivity at the initial presentation of LETM predicts relapse of myelitis or development of optic neuritis.
Gene_expression (presentation) of NMO in optic associated with neuromyelitis optica, transverse myelitis, optic neuritis, demyelinating disease, neuritis and recurrence
14) Confidence 0.04 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1852124 Disease Relevance 2.00 Pain Relevance 0.33
Further studies will have to address the question of whether AQP4 is the only target antigen in NMO, and whether antibodies to AQP4 are pathogenic in NMO or a mere epiphenomenon of the disease.
Gene_expression (pathogenic) of NMO in mere associated with neuromyelitis optica and disease
15) Confidence 0.04 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1852124 Disease Relevance 0.90 Pain Relevance 0.06
Further studies will have to address the question of whether AQP4 is the only target antigen in NMO, and whether antibodies to AQP4 are pathogenic in NMO or a mere epiphenomenon of the disease.
Gene_expression (pathogenic) of NMO in mere associated with neuromyelitis optica and disease
16) Confidence 0.04 Published 2007 Journal PLoS Medicine Section Body Doc Link PMC1852124 Disease Relevance 0.91 Pain Relevance 0.06
The increased sensitivity of AQP4 assays compared with NMO-IgG testing suggests that AQP4 is the main, or possibly the only, target for NMO-IgG [41, 96].
Gene_expression (assays) of NMO associated with neuromyelitis optica
17) Confidence 0.04 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.42 Pain Relevance 0.12
However, NMO-IgG is not detectable in all patients.
Neg (not) Gene_expression (detectable) of NMO associated with neuromyelitis optica
18) Confidence 0.04 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2730746 Disease Relevance 2.14 Pain Relevance 0.32
Recently, widespread absence of detectable AQP4 in spinal cord tissue of NMO lesions has been demonstrated by several groups [65, 80, 85].
Gene_expression (lesions) of NMO in spinal cord associated with neuromyelitis optica and spinal cord
19) Confidence 0.04 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 1.56 Pain Relevance 0.26
The detection of NMO specific serum auto-antibodies, collectively known as NMO-IgG, helps to allows early diagnostic distinction between NMO and MS [54, 56].
Gene_expression (detection) of NMO associated with neuromyelitis optica and multiple sclerosis
20) Confidence 0.04 Published 2010 Journal Current Neuropharmacology Section Body Doc Link PMC2923365 Disease Relevance 2.25 Pain Relevance 0.39

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox